A protective broadly cross-reactive human antibody defines a conserved site of vulnerability on beta-coronavirus spikes

0 views • Nov 6, 2021
0
Save
Cite
Share

Author(s)

Author Name

Panpan Zhou

Published 1 Project

Immunology

Meng Yuan

Published 11 Projects

Immunology Microbiology

Ge Song

Published 1 Project

Immunology

Nathan Beutler

Published 1 Project

Immunology

Namir Shaabani

Published 1 Project

Immunology

Deli Huang

Published 5 Projects

Immunology Microbiology

Wan-ting He

Published 1 Project

Immunology

Sean Callaghan

Published 1 Project

Immunology

Peter Yong

Published 1 Project

Immunology

Fabio Anzanello

Published 1 Project

Immunology

Linghang Peng

Published 4 Projects

Immunology Microbiology

James Ricketts

Published 1 Project

Immunology

Mara Parren

Published 1 Project

Immunology

Elijah Garcia

Published 1 Project

Immunology

Stephen A Rawlings

Published 3 Projects

Immunology Infectious Diseases

Davey M Smith

Published 2 Projects

Immunology

David Nemazee

Published 4 Projects

Immunology Microbiology

John R. Teijaro

Published 1 Project

Immunology

Thomas F Rogers

Published 2 Projects

Immunology Microbiology

Dennis R. Burton

Published 3 Projects

Immunology Microbiology

Raiees Andrabi

Published 1 Project

Immunology

Add New Author

We recently described CC40.8 bnAb from a COVID-19 donor that exhibits broad reactivity with human {beta}-CoVs. Here, we show that CC40.8 targets the conserved S2 stem-helix region of the coronavirus spike fusion machinery. We determined a crystal structure of CC40.8 Fab with a SARS-CoV-2 S2 stem-peptide at 1.6 A resolution and found that the peptide adopts a mainly helical structure. Conserved residues in {beta}-CoVs interact with the antibody, thereby providing a molecular basis for its broad reactivity. CC40.8 exhibits in vivo protective efficacy against SARS-CoV-2 challenge in a hamster model with reduction in weight loss and lung viral titers. Furthermore, we noted CC40.8-like bnAbs are relatively rare in human COVID-19 infection and therefore their elicitation may require rational vaccine strategies. Overall, our study describes a new target on CoV spikes for protective antibodies that may facilitate the development of pan-{beta}-CoV vaccines.

Immunology
Immunology 63 Projects